ANDA 62711, held by Elkins Sinn. Oxacillin Sodium.
As of Nov 15, 2026, ANDA 62711 (Oxacillin Sodium), held by Elkins Sinn, was not approved, with 0 approved supplements and 0 published complete response letters.
| Oxacillin SodiumEQ 250MG BASE/VIAL · injectable;injection | Oxacillin Sodium | Discontinued |
| Oxacillin SodiumEQ 500MG BASE/VIAL · injectable;injection | Oxacillin Sodium | Discontinued |
| Oxacillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Oxacillin Sodium | Discontinued |
| Oxacillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Oxacillin Sodium | Discontinued |
| Oxacillin SodiumEQ 4GM BASE/VIAL · injectable;injection | Oxacillin Sodium | Discontinued |
| Oxacillin SodiumEQ 10GM BASE/VIAL · injectable;injection | Oxacillin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters